Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

Molecular Cytogenetics

Volumn 6, Issue 1, 2013, Pages

  Mosakhani, Neda ^a   Mustjoki, Satu ^a   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CML; Imatinib response; miRNA

Indexed keywords

DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; MICRORNA; MICRORNA 181C; NILOTINIB; UNCLASSIFIED DRUG;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

EID: 84880131014     PISSN: None     EISSN: 17558166     Source Type: Journal    
DOI: 10.1186/1755-8166-6-27     Document Type: Article

References (20)

1. Non-coding RNAs for medical practice in oncology. Setoyama T, Ling H, Natsugoe S, Calin GA, Keio J Med 2011 60 106 113 10.2302/kjm.60.106 22200634
2. MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response. Rukov JL, Shomron N, Trends Mol Med 2011 17 412 423 10.1016/j.molmed.2011.04.003 21652264
3. Chronic myeloid leukemia: An update of concepts and management recommendations of european LeukemiaNet. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, J Clin Oncol 2009 27 6041 6051 10.1200/JCO.2009.25.0779 19884523
4. MicroRNA microarrays on archive bone marrow core biopsies of leukemias-method validation. Borze I, Guled M, Musse S, Raunio A, Elonen E, Saarinen-Pihkala U, Karjalainen-Lindsberg ML, Lahti L, Knuutila S, Leuk Res 2011 35 188 195 10.1016/j.leukres.2010.08.005 20828815
5. MicroRNAs modulate hematopoietic lineage differentiation. Chen CZ, Li L, Lodish HF, Bartel DP, Science 2004 303 83 86 10.1126/science.1091903 14657504 (Pubitemid 38055775)
6. Human activated CD4(+) T lymphocytes increase IL-2 expression by downregulating microRNA-181c. Xue Q, Guo ZY, Li W, Wen WH, Meng YL, Jia LT, Wang J, Yao LB, Jin BQ, Wang T, Yang AG, Mol Immunol 2011 48 592 599 10.1016/j.molimm.2010.10.021 21112091
7. The microRNA miR-181 targets the homeobox protein hox-A11 during mammalian myoblast differentiation. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M, Cuvellier S, Harel-Bellan A, Nat Cell Biol 2006 8 278 84 10.1038/ncb1373 16489342 (Pubitemid 43336070)
8. Detection of a microRNA signal in an in vivo expression set of mRNAs. Liu T, Papagiannakopoulos T, Puskar K, Qi S, Santiago F, Clay W, Lao K, Lee Y, Nelson SF, Kornblum HI, Doyle F, Petzold L, Shraiman B, Kosik KS, PLoS One 2007 2 804 10.1371/journal.pone.0000804 17726534 (Pubitemid 351386574)
9. Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. Chen A, Luo M, Yuan G, Yu J, Deng T, Zhang L, Zhou Y, Mitchelson K, Cheng J, Biotechnol Lett 2008 30 2045 2052 10.1007/s10529-008-9800-8 18648749
10. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: Implications for drug resistance in myelogenous leukemia. Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, Richards KL, Hammond SM, Graves LM, Mol Pharmacol 2010 78 811 817 10.1124/mol.110.066258 20693279
11. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM, Thirman MJ, Golub TR, Rowley JD, Chen J, Proc Natl Acad Sci USA 2008 105 15535 15540 10.1073/pnas.0808266105 18832181
12. Down-regulated expression of hsa-miR-181c in fanconi anemia patients: Implications in TNFalpha regulation and proliferation of hematopoietic progenitor cells. Rio P, Agirre X, Garate L, Banos R, Alvarez L, San Jose-Eneriz E, Badell I, Casado JA, Garin M, Prosper F, Bueren JA, Blood 2012 119 3042 3049 10.1182/blood-2011-01-331017 22310912
13. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. San Jose-Eneriz E, Roman-Gomez J, Jimenez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodriguez-Otero P, Calasanz MJ, Prosper F, Agirre X, Mol Cancer 2009 8 69 10.1186/1476-4598-8-69 19723306
14. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JE, Haematologica 2010 95 1325 1333 10.3324/haematol.2009.020636 20460641
15. Expression patterns of microRNAs associated with CML phases and their disease related targets. Machova Polakova K, Lopotova T, Klamova H, Burda P, Trneny M, Stopka T, Mol Cancer 2011 10 41 10.1186/1476-4598-10-41 21501493
16. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD, Chen J, Blood 2012 119 2314 2324 10.1182/blood-2011-10-386235 22251480
17. Identification of potential chemoresistance genes in osteosarcoma. Walters DK, Steinmann P, Langsam B, Schmutz S, Born W, Fuchs B, Anticancer Res 2008 28 673 679 18507006 (Pubitemid 351578907)
18. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Xu H, Yan M, Patra J, Natrajan R, Yan Y, Swagemakers S, Tomaszewski JM, Verschoor S, Millar EK, van der Spek P, Reis-Filho JS, Ramsay RG, O'Toole SA, McNeil CM, Sutherland RL, McKay MJ, Fox SB, Breast Cancer Res 2011 13 9 10.1186/bcr2814 21255398
19. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival. Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, Zhu PH, Sardana G, Chen J, Kupchak P, Jacks LM, Miller NA, Youngson BJ, Iakovlev V, Guidos CJ, Vallis KA, Evans KR, McCready D, Leong WL, Done SJ, PLoS One 2012 7 30992 10.1371/journal.pone.0030992 22363530
20. Effect of heat shock protein-90 (HSP90) and vascular endothelial growth factor (VEGF) on survival in acute lymphoblastic leukemia: an immunohistochemical study. Hacihanefioglu A, Gonullu E, Mehtap O, Keski H, Yavuz M, Ercin C, Med Oncol 2011 28 846 851 10.1007/s12032-010-9533-0 20422320